As drugmakers strive to fine tune the delivery of their medications for better convenience and patient adherence, Halozyme is putting a recent acquisition in the space to work, thanks to a new tie- | ...

Halozyme Therapeutics (NASDAQ:HALO) said its subsidiary has entered into an exclusive collaboration and licensing agreement with Vertex Pharmaceuticals (NASDAQ:VRTX) covering the use of Halozyme’s ...

Vertex Pharmaceuticals makes most of its money from the sale of medicines for cystic fibrosis (CF), a rare disease that ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, ...

Vertex Pharmaceuticals is acquiring immune therapies developer Alpine Immune Sciences in a $4.9 billion deal whose centerpiece is a Phase 3-ready drug for a chronic kidney disorder with few treatment ...

Vertex Pharmaceuticals stock is a "Strong Buy", driven by robust CF franchise growth and successful label expansions for ...

Security researchers have identified a vulnerability in Google’s Vertex AI agent framework that could allow attackers to ...

Unit 42 found excessive P4SA permissions in Vertex AI, enabling credential theft and cloud data exposure, increasing breach ...